Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biovet JSCLTS:0III ROC (Joel Greenblatt) % is 13.76% as of Dec. 2016, which is 28% above its 10-year median of 10.74. The stock has 1 warning sign investors should review.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Biovet JSC's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2016 was 13.76%.
The historical rank and industry rank for Biovet JSC's ROC (Joel Greenblatt) % or its related term are showing as below:
LTS:0III'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 4.62 Med: 10.74 Max: 14.69
Current: 11.13
During the past 8 years, Biovet JSC's highest ROC (Joel Greenblatt) % was 14.69%. The lowest was 4.62%. And the median was 10.74%.
LTS:0III's ROC (Joel Greenblatt) % is not ranked
in the Drug Manufacturers industry.
Industry Median: 11.46
vs LTS:0III: 11.13
Biovet JSC's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 13.30% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Biovet JSC ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Biovet JSC's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0III vs ADMP, AGRX, BUDZ: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biovet JSC's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biovet JSC ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biovet JSC's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Biovet JSC's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Dec. 2016) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 13.76% mean?
Biovet JSC (LTS:0III) has a ROC (Joel Greenblatt) % of 13.76% as of Dec. 2016. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Biovet JSC and its competitors. This is 28% above median its historical median of 10.74. Over the past decade, Biovet JSC's ROC (Joel Greenblatt) % has ranged from 4.62 to 14.69.
Is Biovet JSC's ROC (Joel Greenblatt) % too high?
Biovet JSC's current ROC (Joel Greenblatt) % of 13.76% is 28% above median its 10-year median of 10.74. Over the past 10 years, this metric has ranged from a low of 4.62 to a high of 14.69. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.46. Biovet JSC's value of 13.76% is 20.1% above this industry median.
How does Biovet JSC's ROC (Joel Greenblatt) % compare to ADMP and AGRX?
Biovet JSC's ROC (Joel Greenblatt) % of 13.76% can be compared against companies in the Drug Manufacturers industry. The industry median ROC (Joel Greenblatt) % is 11.46. Biovet JSC's value of 13.76% is 20.1% above this benchmark. Historically, Biovet JSC's own ROC (Joel Greenblatt) % has ranged from 4.62 to 14.69 over the past decade. While the company's 10-year median is 10.74 vs. the industry median of 11.46, Biovet JSC has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.46, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biovet JSC's current ROC (Joel Greenblatt) % of 13.76% is 20.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Biovet JSC and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biovet JSC's current ROC (Joel Greenblatt) % is 13.76%, which is 28% above median its own 10-year median of 10.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biovet JSC stock overvalued right now?
Biovet JSC (LTS:0III) has a current ROC (Joel Greenblatt) % of 13.76%. The current ROC (Joel Greenblatt) % is 13.76%, which is 28% above median its 10-year median of 10.74 and 20.1% above the Drug Manufacturers industry median of 11.46. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Biovet JSC (LTS:0III), the current ROC (Joel Greenblatt) % is 13.76% as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biovet JSC manufactures & markets medicated and nutritional feed additives, enzymes, bulk active substances & pharmaceuticals for animal productivity & health. It offers intermediates, active ingredients and medicines for human pharmaceutical industry.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0III has been successfully added to your 
